Spark Therapeutics, every mention
6 scenes · ← back to Spark Therapeutics
tap a year for its mentions
every year anyone Koki Hirasaki 6Nate Chang 4Jorge Conde 1
Verbatim, from the transcripts: the passages where Spark Therapeutics comes up
What’s with All the Bio M&A in 2019?: A Quick Take
- ▶ 3:19 Nate Chang If you look at, um, Spark, which got announced yesterday, they had a lot of nice tailwinds in the hemophilia franchise, and Roche really looked at their Heme 2 times in the scene
- ▶ 4:39 Nate Chang Avexis emerging in gene therapy, with Luxeterna and the other Spark programs emerging in hemophilia, I think those two buyers really felt that those are going to be the leading platforms in those, in, in gene therapy. 2 times in the scene
- ▶ 5:59 Koki Hirasaki And then, uh, with the Spark, uh, uh, acquisition, um, same thing, uh, BMS, I'm sorry, uh, Roche was a laggard in the space, and, um, now suddenly leaped ahead with not only, uh, a marketed gene therapy, but, um, this, uh, AAV platform… 2 times in the scene
- ▶ 16:10 Koki Hirasaki Um, and then, you know, there are other considerations later on where, uh, some big pharma companies will just tend to fully integrate, uh, the, the company, uh, whereas others will, uh, like Roche and Spark will, uh, allow the, the…
- ▶ 19:27 Koki Hirasaki And so, what you see are, in this fairly typical, uh, and actually Spark is a good example, where, um, the company will keep, uh, commercial rights for the U.S. 3 times in the scene
Challenges in Healthcare Innovation
- ▶ 16:39 Jorge Conde We've also seen in the news how Kite Pharma and Spark Therapeutics are bringing us cell therapies and gene therapies.